Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 5Thyroid Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Sarcoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Thymus Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Skin Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1

Interventions

romidepsin 1amino-acid, glucose, and electrolyte solution 1Lactones 1Fluorodeoxyglucose F18 1Depsipeptides 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Fluorodeoxyglucose F18 × NET × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Enrolling by invitation
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡